Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Request metadata listed "Niagen Bioscience, Inc.", but the filing identifies the registrant as ChromaDex Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2017 (Event Date); June 12, 2017 (Signature Date)
Context: The Company entered into a strategic partnership with the Scripps Research Institute (TSRI) to advance cancer therapy research, specifically focusing on breast cancer and nicotinamide adenine dinucleotide redox balancing.
Key Financial Metrics and Agreements
This filing details a Material Definitive Agreement rather than periodic financial results. Key financial terms include:
- Upfront Cash Payment: $50,000 payable to TSRI within 15 days of closing.
- Research Funding: Aggregate funding of up to approximately $2.0 million over three years, paid in installments.
- Annual Fees: Ranging from $50,000 to $100,000, credited against future royalties.
- Milestone Payments: Product development milestones ranging from low-six figures to low-eight figures.
- Royalties: Mid-single digit percentage on net sales of licensed products.
- Patent Costs: Reimbursement of certain costs for patent preparation, filing, and maintenance.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the Company.
Material Changes
The primary material change is the execution of two new agreements on June 9, 2017:
- License Agreement: Grants ChromaDex a worldwide, exclusive, royalty-bearing license to TSRI patent rights regarding methods and compositions for enhancing cancer therapy.
- Research Funding Agreement: Commences a three-year research program funded by ChromaDex to study nicotinamide riboside for enhancing endocrine therapy and preventing breast cancer relapse.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to use reasonable efforts to develop and market the licensed products. A press release announcing the agreements was issued on June 12, 2017.
Termination Risks:
- License Agreement: May be terminated by mutual consent or by TSRI if ChromaDex fails to make due payments and does not cure the default within 30 days of notice.
- Research Funding Agreement: May be terminated by ChromaDex with 90 days' written notice or by either party upon failure to perform obligations.
Confidentiality: Certain portions of the agreements are subject to a request for confidential treatment and will be filed as exhibits to the Form 10-Q for the quarter ending July 1, 2017.
Investor Verification Checklist
- Verify the exact terms of the "low-six digit" to "low-eight digit" milestone payments in the full agreement text.
- Confirm the specific "mid-single digit" royalty percentage once the confidential treatment request is resolved or the 10-Q is filed.
- Monitor the Company's cash position to ensure it can meet the $50,000 upfront payment and the initial research funding installment due within 10 days.
- Review the upcoming Form 10-Q (due for the quarter ending July 1, 2017) for the full text of the agreements and any impact on the Company's financial statements.